Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03681223 · ClinicalTrials.gov registry record · NA
Restorelle® Y Mesh vs. Vertessa® Lite Y Mesh for Laparoscopic and Robotic-assisted Laparoscopic Sacrocolpopexy
A NA study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- NA
- Development phase
- 106
- Enrollment target
NCT03681223: Completed NA study, sponsored by The Cleveland Clinic.
NCT03681223 is a NA study that has completed, run by The Cleveland Clinic. The registered enrollment target is 106 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03681223, a NA study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 106 participants
- Enrollment target
Study Summary
This is a randomized clinical trial to compare outcomes between the Restorelle® Y mesh and Vertessa® lite Y mesh for the treatment of vaginal vault prolapse. Hypothesis: Vertessa® lite Y mesh is not inferior to Restorelle® Y mesh for the treatment of vaginal vault prolapse
Primary Outcome
Retreatment for prolapse by either surgery or pessary
Interventions
- DEVICE Vertessa® Lite Y mesh
- DEVICE Restorelle® Y mesh
- PROCEDURE Laparoscopic sacrocolpopexy
- PROCEDURE Robotic assisted laparoscopic sacrocolpopexy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2018-09-18 |
| Est. Completion | 2023-12-19 |
| Phase | NA |
What the finished NCT03681223 record still lists
NCT03681223 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 4 interventions - of which Vertessa® Lite Y mesh is the first listed.
NCT03681223 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03681223 about?
NCT03681223 is a clinical study titled "Restorelle® Y Mesh vs. Vertessa® Lite Y Mesh for Laparoscopic and Robotic-assisted Laparoscopic Sacrocolpopexy". This is a randomized clinical trial to compare outcomes between the Restorelle® Y mesh and Vertessa® lite Y mesh for the treatment of vaginal vault prolapse. Hypothesis: Vertessa® lite Y mesh is not inferior to Restorelle® Y mesh for the treatment of vaginal vault prolapse
What is the current status of trial NCT03681223?
This trial is currently completed. It is a NA study. The enrollment target is 106 participants. The study started on 2018-09-18. Estimated completion is 2023-12-19.
What interventions are being tested in trial NCT03681223?
The interventions under investigation include: Vertessa® Lite Y mesh (DEVICE), Restorelle® Y mesh (DEVICE), Laparoscopic sacrocolpopexy (PROCEDURE), Robotic assisted laparoscopic sacrocolpopexy (PROCEDURE).
Who is sponsoring clinical trial NCT03681223?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03681223's enrollment target sits among peer trials
106 830th of 2000 higher than 1,167 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI